Wai Chung Wong

Wai Chung Wong

Auto-generated profile, based on publicly available information

Wai Chung Wong

Nuclear Medicine Unit, Department of Diagnostic and Interventional Radiology, Queen Elizabeth Hospital, Hong Kong, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Radiology Case Reports
Verified
Journal Article
Open access
JLJeremy Hugh Yen-Hey Lau
Jeremy Hugh Yen-Hey Lau
KNKoon Kiu Ng
Koon Kiu Ng
WWWai Chung Wong
Wai Chung Wong
BKBoom Ting Kung
Boom Ting Kung
Gastrointestinal bleeding is a common condition requiring urgent medical attention. 99mTc-labeled red blood cell scintigraphy is a conventional nuclear medicine imaging technique which is sensitive and noninvasive for diagnosing occult gastrointestinal bleeding. However, there are pitfalls in this technique due to 2D representation in planar images and altered biodistribution in certain physiological status of the patient. The anatomical localization of single-photon emission computerized tomographycomputed tomography (SPECT/CT) can avoid these pitfalls and reduce equivocal findings in Tc99m-labeled red blood cell scintigraphy. This case series review demonstrates equivocal findings in 99mTc-labeled red blood cell scintigraphy, with the help of SPECT/CT, were found to be possible blood pooling in vasculatures and hemolysis after blood transfusion.

3 May 2024 in Radiology Case Reports
Verified
Journal Article
Open access
JLJeremy Hugh Yen-Hey Lau
Jeremy Hugh Yen-Hey Lau
KNKoon Kiu Ng
Koon Kiu Ng
WWWai Chung Wong
Wai Chung Wong
BKBoom Ting Kung
Boom Ting Kung
An 18-year-old male with multiple endocrine neoplasm type 1 (MEN1) syndrome presented with hyperparathyroidism. Parathyroidectomy was performed. Patient complained of bone pain afterwards, multiple imaging modalities revealed features of osteitis fibrosa cystica and biochemical profile showed features of hungry bone syndrome. Incidental suspicious pancreatic lesion was initially revealed by 18F-FDG PET/CT scan while MRI further characterized the possibility of insulinoma. Ultimately, the patient was diagnosed of MEN1 syndrome by genetic test. This case report demonstrates the utilization of various imaging modalities such as ultrasound, Tc99m-sestamibi parathyroid scintigraphy, bone scintigraphy, CT, PET/CT and MRI, which leads to ultimately the diagnosis of MEN1 syndrome.


23 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ELEvelyn Lu
Evelyn Lu
CHCalvin P. L. Hoo
Calvin P. L. Hoo
HCHo Ming Cheung
Ho Ming Cheung
IWI. W. C. Wong
I. W. C. Wong
KFKin Fen Kevin Fung
Kin Fen Kevin Fung
GCGodfrey C. F. Chan
Godfrey C. F. Chan
Background: The integration of anti-disialoganglioside GD2 (anti-GD2) immunotherapy during induction chemotherapy has emerged as a promising strategy to improve outcomes in high-risk neuroblastoma (HR-NB). This study evaluated the end-of-induction (EOI) response and tolerability of a modified N7 induction regimen combined with dinutuximab beta in a Hong Kong paediatric cohort. Methods: A retrospective territory-wide analysis was conducted on nine HR-NB patients treated from 2022 to 2025. They received a modified N7 chemotherapy backbone with dinutuximab beta (17.5 mg/m2/day for 4 days per cycle), alongside granulocyte–macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin-2. Response was assessed using the Revised International Neuroblastoma Response Criteria (INRC), and toxicity was graded according to the Common Terminology Criteria for adverse events (CTCAE). Results: The EOI objective response rate was 78% (7/9 patients) for the primary tumour site and 100% at metastatic sites. No patient exhibited progressive disease. A modified Curie score of ≤2 on MIBG scan was achieved in 78% of patients. Grade 3 or higher toxicities, including neutropenic fever, enterocolitis, and capillary leak syndrome, were observed in eight patients but were manageable. Conclusions: The incorporation of dinutuximab beta into a modified N7 induction regimen demonstrates a satisfactory EOI response rate and a manageable safety profile in children with HR-NB. These preliminary results support the feasibility of this chemoimmunotherapy approach and warrant further investigation in larger cohorts to confirm its efficacy in long-term survival outcomes.